SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMetir Plc Regulatory News (MET)

Share Price Information for Metir Plc (MET)

Share Price is delayed by 15 minutes
Get Live Data
0.85    0.00 (0.00%)
Bid:
0.80
Ask:
0.90
Spread: 0.10 (12.50%)
Market Cap: £3.77m
MET Live PriceLast checked at - London Stock Exchange

Intraday Metir Plc Share Chart

Trading Statement

13 Jan 2026 07:00

RNS Number : 6056O
Metir PLC
13 January 2026
 

 

13 January 2026

Metir plc

 

("Metir", the "Group" or the "Company")

 

Trading Update

 

Metir plc (AIM: MET), the leading global provider of fast-response, mobile and point-of-use water and environmental monitoring technologies, is pleased to provide a trading update for the financial year ended 31 December 2025 ("FY25"). The Group's Annual Report and Accounts are expected to be published in May 2026.

 

Trading in FY25 was in line with management expectations, with growth driven by increased international demand for Microtox® LX instruments, Microtox® reagents and Sulphate Reducing Bacteria ("SRB") kits, alongside continued progress in large-scale potable water monitoring projects with the Continuous Toxic Monitoring ("CTM") installation in Qatar. The Group expects to report revenues of £1.5m (31 December 2024: £0.23m) and a cash balance at the year-end of £1.04m following the successful fundraise of £1.0m, before expenses, completed on 22 December 2025.

 

The Group has continued to build on the momentum reported in its interim results announced on 30 September 2025 and the trading update released on 2 December 2025. Customer demand for Microtox® LX instruments remained strong throughout the second half of the year. Although outsourced manufacturing output increased during H2 2025, production capacity was limited during Q4 2025, constraining the pace at which customer demand could be converted into revenue. Due to these restrictions, 10 of the 56 Microtox® LX instruments ordered in FY25 could not be fulfilled; however, they are now being manufactured and will be delivered in early 2026. Increasing the outsourced manufacturing capacity of Microtox® FX instruments is a key near-term objective in 2026 following increased sales interest.

 

The growing installed base of Microtox® LX and FX instruments is expected to drive demand for high-margin Microtox® reagents. The Board believes that unlocking this high-margin recurring revenue stream is a significant financial objective for the business, with a focus on not only increasing manufacturing capacity, but also working with customers to drive greater reagent usage.

 

Demand for SRB kits, which were relaunched in June 2025, remained robust. Customer interest increased materially, with quotations provided to more than 60 companies worldwide. During Q4 2025, production of SRB kits was temporarily paused due to a manufacturing quality control assessment. The objective is to restart production as soon as practicable, possibly using an alternative biological component to ensure Modern Water's QuickChek™ SRB kit remains the market-leading fast response product.

 

Throughout FY25, the Board continued to prioritise investment in scaling-up manufacturing, product development and commercial capability, consistent with the Group's strategy to build a growing recurring-revenue business for its current product range. In addition, Metir is developing what it believes could be significant future revenue streams from new technologies, including its proprietary mobile PFAS testing technology with Swansea University, and progressing towards completion of the Cryptosporidium project in 2026 with Aptamer Group plc for deployment of a commercial real-time continuous Pathogen Detector.

 

The Group completed a fundraising in December 2025 to strengthen working capital, accelerate manufacturing output and therefore support the conversion of a growing order book into revenue. The Board believes this additional funding materially improves the Group's ability to execute its near-term growth plans and to increase margins on its products.

 

Metir has growing revenues from multiple and diverse Modern Water product streams. Ongoing development of the Group's unique mobile PFAS detection and Pathogen Detection technologies will increase the product portfolio further.

 

Bob Moore, Executive Chairman and Chief Executive Officer of Metir plc, commented:

 

"FY25 marked a year of strong commercial progress for Metir, with customer demand continuing to grow across Modern Water's instrument, reagent and testing kit portfolio. While manufacturing capacity constrained the Group's ability to fully meet demand during the year, the underlying momentum in the business is encouraging for sales growth throughout 2026.

 

"With enhanced funding in place, a growing installed base of instruments and an expanding international pipeline, we enter this year with increased confidence. The Board believes the actions taken during FY25, including further product development, provide a solid foundation for accelerating production of the Group's instrumentation and reagents, driving revenue growth and progressing towards sustainable profitability.

 

"We look forward to reporting progress on the Group's growth initiatives over the coming months."

 

- Ends -

 

Enquiries:

 

Metir plc

Bob Moore, Executive Chairman and Chief Executive Officer

+44 (0) 20 3657 0050

via TPI

 

 

Singer Capital Markets(Nominated Adviser & Joint Broker)

Alex Bond

+44 (0)20 7496 3000

 

 

Turner Pope Investments (TPI) Limited(Joint Broker)

Andrew Thacker / Guy McDougall 

+44 (0) 20 3657 0050

 

Northstar Communications (Investor Relations)

Sarah Hollins

+44 (0) 113 730 3896

 

About Metir

 

Metir plc is a leading global provider of several fast-response, mobile and point-of-use water and environmental monitoring technologies. Through its two established trading divisions, Modern Water and Microsaic Systems, a specialist in mobile PFAS monitoring, the Company develops and supplies innovative, easy-to-use solutions that deliver rapid, accurate water and liquids quality results, helping industries, utilities and regulators monitor safety and compliance in real time.

 

With a strong focus on data-driven insight and field-ready design, Metir's technology supports critical decision-making across sectors, including environmental monitoring, public health and industrial process management.

 

Headquartered in York, UK, Metir serves worldwide customers and is dedicated to advancing water testing standards through innovative, accessible solutions.

 

For more information, please visit: https://www.metirplc.com 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTDXGDBGSBDGLD
Date   Source Headline
4th Jun 20267:00 amRNSMajor Commercial Advances for PFAS Platform
20th Apr 20267:00 amRNSAppointment of Three New Distributors
25th Mar 20267:00 amRNSContinuous Toxicity Monitoring Project Update
24th Feb 20267:00 amRNS-RInvestor Webinar
17th Feb 20267:00 amRNSTechnical Feasibility for Pathogen Detector
16th Feb 20268:53 amRNSHolding(s) in Company
16th Feb 20268:52 amRNSHolding(s) in Company
16th Feb 20268:52 amRNSHolding(s) in Company
10th Feb 20267:00 amRNSAppointment of Nominated Adviser
13th Jan 20267:00 amRNSTrading Statement
22nd Dec 20257:00 amRNSFundraise
2nd Dec 20257:00 amRNSTrading Update and Growth Plan
19th Nov 20257:00 amRNSCFO Appointment
4th Nov 20257:00 amRNS-RAdvancement of PFAS detection technology
30th Sep 20257:00 amRNSHalf-year Report
26th Sep 20257:00 amRNSFinal Commissioning of Qatar Project
11th Sep 20257:00 amRNSNew Contract with Aptamer Group
12th Aug 202512:30 pmRNSResult of AGM
31st Jul 20257:00 amRNSInterim Trading Update
21st Jul 20259:23 amRNSDirector Participation in Fundraising & TVR
11th Jul 20257:00 amRNSNotice of AGM & Posting of Annual Report
10th Jul 20252:30 pmRNSRestoration - Metir PLC
10th Jul 20252:30 pmRNSFinal Results
4th Jul 20254:16 pmRNSUpdate re. Publication of Annual Report & Accounts
1st Jul 20257:30 amRNSSuspension - Metir PLC
30th Jun 20254:53 pmRNSPublication of Annual Report & Accounts
25th Jun 202512:33 pmRNSHolding(s) in Company
24th Jun 202511:06 amRNSHolding(s) in Company
10th Jun 20257:00 amRNSFundraise
29th May 20257:00 amRNSTrading Update
13th May 20259:15 amRNSHolding(s) in Company
31st Mar 20257:00 amRNSOperational Update
2nd Sep 201411:02 amRNSResult of EGM
7th Aug 201410:53 amRNSProposed Cancellation of Trading on AIM
31st Jul 20147:00 amRNSProposed cancellation of admission to trade on AIM
23rd Jul 20143:40 pmRNSHolding(s) in Company
23rd Jul 201411:20 amRNSResult of AGM
15th Jul 201412:06 pmRNSHolding(s) in Company
15th Jul 20147:30 amRNSSuspension - Metro Baltic Horizons Plc
14th Jul 20143:57 pmRNSProposed Cancellation of Trading on AIM
30th Jun 20142:13 pmRNSNotice of AGM & posting of Accounts replacement
30th Jun 20147:00 amRNSNotice of AGM & posting of Financial Statements
20th Jun 20149:03 amRNSFinal Results
13th Jun 20141:56 pmRNSPreliminary Results Update
9th May 20145:27 pmRNSHolding(s) in Company
9th May 20143:25 pmRNSProposed Suspension of Trading and delisting
6th May 20143:15 pmRNSSettlement Agreement reached with former Auditors
28th Mar 201410:13 amRNSSettlement Agreement
17th Oct 201311:13 amRNSHolding(s) in Company
10th Oct 20133:15 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.